NASDAQ:CALA - Calithera Biosciences Stock Price, Price Target & More

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences Inc (NASDAQ:CALA) announced its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.05. The biotechnology company earned $5.19 million during the quarter, compared to analysts' expectations of $7.28 million. Calithera Biosciences had a negative return on equity of 22.92% and a negative net margin of 131.51%. View Calithera Biosciences' Earnings History.

3 Wall Street analysts have issued 12 month price targets for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they expect Calithera Biosciences' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 197.9% from the stock's current price. View Analyst Ratings for Calithera Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Calithera Biosciences saw a drop in short interest during the month of June. As of June 29th, there was short interest totalling 1,468,140 shares, a drop of 32.1% from the June 15th total of 2,163,551 shares. Based on an average daily trading volume, of 622,955 shares, the days-to-cover ratio is currently 2.4 days. Approximately 5.1% of the company's stock are sold short. View Calithera Biosciences' Current Options Chain.

Some companies that are related to Calithera Biosciences include ChemoCentryx (CCXI), Vectura Group (VEGPF), Kura Oncology (KURA), Dicerna Pharmaceuticals (DRNA), Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Odonate Therapeutics (ODT), Aclaris Therapeutics (ACRS), Geron (GERN), Evolus (EOLS), Progenics Pharmaceuticals (PGNX) and Innovate Biopharmaceuticals (INNT).

Headlines about CALA stock have been trending somewhat positive on Tuesday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.20 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CALA stock can currently be purchased for approximately $4.70.

Calithera Biosciences has a market capitalization of $170.26 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]